Bright Short Term Debt vs Net Receivables Analysis
DRUG Stock | USD 38.59 3.26 9.23% |
Bright Minds financial indicator trend analysis is way more than just evaluating Bright Minds Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bright Minds Biosciences is a good investment. Please check the relationship between Bright Minds Short Term Debt and its Net Receivables accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Short Term Debt vs Net Receivables
Short Term Debt vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bright Minds Biosciences Short Term Debt account and Net Receivables. At this time, the significance of the direction appears to have pay attention.
The correlation between Bright Minds' Short Term Debt and Net Receivables is -0.86. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Bright Minds Biosciences, assuming nothing else is changed. The correlation between historical values of Bright Minds' Short Term Debt and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Bright Minds Biosciences are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Short Term Debt i.e., Bright Minds' Short Term Debt and Net Receivables go up and down completely randomly.
Correlation Coefficient | -0.86 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Short Term Debt
Net Receivables
Most indicators from Bright Minds' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bright Minds Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. The current Selling General Administrative is estimated to decrease to about 1.3 M. The current Issuance Of Capital Stock is estimated to decrease to about 1 M
Bright Minds fundamental ratios Correlations
Click cells to compare fundamentals
Bright Minds Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bright Minds fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 880.2K | 20.0M | 12.1M | 6.9M | 7.9M | 8.8M | |
Other Current Liab | 12.5K | 42K | 158.2K | 25K | 28.8K | 27.3K | |
Total Current Liabilities | 150.9K | 638.6K | 1.5M | 280.9K | 323.0K | 567.5K | |
Total Stockholder Equity | 729.3K | 19.4M | 10.5M | 6.6M | 7.6M | 8.2M | |
Net Debt | (799.9K) | (19.8M) | (11.5M) | (6.7M) | (6.0M) | (6.3M) | |
Retained Earnings | (559.1K) | (9.2M) | (24.2M) | (31.5M) | (28.4M) | (27.0M) | |
Accounts Payable | 138.4K | 596.6K | 1.2M | 182.3K | 209.7K | 199.2K | |
Cash | 799.9K | 19.8M | 11.6M | 6.7M | 7.8M | 8.6M | |
Cash And Short Term Investments | 799.9K | 19.8M | 11.6M | 6.7M | 7.8M | 8.6M | |
Liabilities And Stockholders Equity | 880.2K | 20.0M | 12.1M | 6.9M | 7.9M | 8.8M | |
Other Stockholder Equity | 0.0 | (33.7K) | 10.5T | 831.8K | 956.6K | 908.8K | |
Total Liab | 150.9K | 638.6K | 1.5M | 280.9K | 323.0K | 583.3K | |
Total Current Assets | 878.2K | 20.0M | 11.9M | 6.8M | 7.8M | 8.7M | |
Accumulated Other Comprehensive Income | 161.3K | 1.6M | 2.5M | 4.2M | 4.9M | 5.1M | |
Common Stock | 980.7K | 27.1M | 32.2M | 33.9M | 39.0M | 20.8M |
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.